ADMA Biologics Stockholders Vote to Approve Acquisition of Certain Assets from Biotest Pharmaceuticals Corporation

Home/Lifesci News/ADMA Biologics Stockholders Vote to Approve Acquisition of Certain Assets from Biotest Pharmaceuticals Corporation

ADMA Biologics Stockholders Vote to Approve Acquisition of Certain Assets from Biotest Pharmaceuticals Corporation

RAMSEY, N.J., May 30, 2017 (GLOBE NEWSWIRE) — ADMA Biologics, Inc. (ADMA) announced today that its stockholders voted to approve ADMA’s previously announced acquisition of certain assets from Biotest Pharmaceuticals Corporation (BPC), a wholly-owned subsidiary of Biotest AG, at ADMA’s annual meeting of stockholders held on May 25, 2017.  ADMA is a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the proposed treatment of immune deficiencies and prevention of certain infectious diseases.

2017-08-07T14:58:13+00:00